Deborah Harland Partner, SR One

Deborah joined SR One in 2005 and leads SR One's investment activities in Europe. She is currently a member of the Board of Directors of Protaffin AG, Bicycle Therapeutics Limited, Syntaxin Limited, and F-star GmbH and is an observer on the board of 7TM Pharma. Deborah was previously a member of the Board of Directors of Addex Pharmaceuticals (IPO, SIX Swiss Exchange, 2007) and Pharmakodex Limited (sold to Orexo) and an observer on the Board of Ablynx (IPO, Euronext Brussels 2007). Deborah has extensive drug development experience, gained during her
13 year tenure in the clinical development teams of Marion Merrell Dow and SmithKline Beecham where she was responsible for design, management and reporting of phase I, II, II and IV multinational clinical trials across several therapeutic areas and for providing medical marketing support for marketed products in the cardiovascular and CNS areas. Immediately prior to
SR One, Deborah spent over four years with GSK's Worldwide Business Development team where she evaluated in-licensing opportunities in the CNS and GI therapeutic areas. Deborah holds a BSc. (Hons.) in Pharmacology from the University of Bath, a PhD in Pharmacology from the University of London, and an MBA from Henley Management College